AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 147 filers reported holding AGIOS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $763 | +151.8% | 14,510 | +35.7% | 0.00% | +100.0% |
| Q2 2023 | $303 | +23.2% | 10,691 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $246 | -18.0% | 10,691 | 0.0% | 0.00% | -50.0% |
| Q4 2022 | $300 | -99.9% | 10,691 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $302,000 | +27.4% | 10,691 | 0.0% | 0.00% | +100.0% |
| Q2 2022 | $237,000 | -23.8% | 10,691 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $311,000 | -12.4% | 10,691 | -1.0% | 0.00% | 0.0% |
| Q4 2021 | $355,000 | -28.7% | 10,796 | 0.0% | 0.00% | -50.0% |
| Q3 2021 | $498,000 | -16.3% | 10,796 | 0.0% | 0.00% | -33.3% |
| Q2 2021 | $595,000 | +6.6% | 10,796 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $558,000 | +19.2% | 10,796 | 0.0% | 0.00% | +50.0% |
| Q4 2020 | $468,000 | +23.8% | 10,796 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $378,000 | -34.5% | 10,796 | 0.0% | 0.00% | -33.3% |
| Q2 2020 | $577,000 | +50.7% | 10,796 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $383,000 | -25.8% | 10,796 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $516,000 | +47.4% | 10,796 | 0.0% | 0.00% | +50.0% |
| Q3 2019 | $350,000 | -35.1% | 10,796 | 0.0% | 0.00% | -33.3% |
| Q2 2019 | $539,000 | -50.8% | 10,796 | -33.5% | 0.00% | -57.1% |
| Q1 2019 | $1,095,000 | +236.9% | 16,230 | +130.4% | 0.01% | +250.0% |
| Q4 2018 | $325,000 | -40.4% | 7,044 | -0.3% | 0.00% | -33.3% |
| Q3 2018 | $545,000 | -8.6% | 7,066 | -0.1% | 0.00% | -25.0% |
| Q2 2018 | $596,000 | +3.1% | 7,075 | +0.1% | 0.00% | 0.0% |
| Q1 2018 | $578,000 | +49.4% | 7,069 | +4.4% | 0.00% | +100.0% |
| Q4 2017 | $387,000 | -10.8% | 6,769 | +4.1% | 0.00% | -33.3% |
| Q3 2017 | $434,000 | +29.6% | 6,505 | +0.0% | 0.00% | +50.0% |
| Q2 2017 | $335,000 | -7.2% | 6,504 | +5.2% | 0.00% | -33.3% |
| Q1 2017 | $361,000 | +39.9% | 6,181 | -0.2% | 0.00% | +50.0% |
| Q4 2016 | $258,000 | -20.1% | 6,194 | +1.3% | 0.00% | -33.3% |
| Q3 2016 | $323,000 | +26.2% | 6,113 | +0.0% | 0.00% | +50.0% |
| Q2 2016 | $256,000 | +4.5% | 6,110 | +1.4% | 0.00% | 0.0% |
| Q1 2016 | $245,000 | -31.0% | 6,028 | +10.3% | 0.00% | -33.3% |
| Q4 2015 | $355,000 | -7.8% | 5,465 | +0.1% | 0.00% | 0.0% |
| Q3 2015 | $385,000 | -36.6% | 5,457 | -0.2% | 0.00% | -40.0% |
| Q2 2015 | $607,000 | +38.9% | 5,466 | +18.0% | 0.01% | +25.0% |
| Q1 2015 | $437,000 | – | 4,634 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |